Tolvaptan Treatment for Autosomal Dominant Polycystic Kidney Disease
Shared Decision Making for Choosing Autosomal DOminant Polycystic Kidney Disease Treatment
- Age
- 18 – 80
- Sex
- Any
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 340 (estimated)
- Sponsor
- Seoul National University Hospital · Other
This trial is looking for adults between 18 and 80 years old who have a specific type of kidney disease called ADPKD. Participants will help evaluate a decision-making model for choosing Tolvaptan as a treatment.
You may be able to join if
- I am between 18 and 80 years old.
- I have been diagnosed with chronic kidney disease stage 2 or 3.
- I have been diagnosed with ADPKD classified as 1C, 1D, or 1E.
- I can communicate and use digital devices.
- I do not have severe visual impairment.
- I do not have cognitive dysfunction.
You may not be able to join if
- I have previously been treated with tolvaptan.
- I am not allowed to take tolvaptan.
- I have been judged ineligible by the investigator.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your EligibilityThe purpose of this study is to generate clinical evidence and assess the feasibility of a shared decision-making (SDM) model for the selection of Tolvaptan in patients with ADPKD.
Loading trial locations…